225 related articles for article (PubMed ID: 16528528)
21. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.
Lenz HJ; Hayashi K; Salonga D; Danenberg KD; Danenberg PV; Metzger R; Banerjee D; Bertino JR; Groshen S; Leichman LP; Leichman CG
Clin Cancer Res; 1998 May; 4(5):1243-50. PubMed ID: 9607583
[TBL] [Abstract][Full Text] [Related]
22. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
Licitra L; Suardi S; Bossi P; Locati LD; Mariani L; Quattrone P; Lo Vullo S; Oggionni M; Olmi P; Cantù G; Pierotti MA; Pilotti S
J Clin Oncol; 2004 Dec; 22(24):4901-6. PubMed ID: 15611505
[TBL] [Abstract][Full Text] [Related]
23. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
24. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Nagase H; Uchida J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):285-91. PubMed ID: 22752215
[TBL] [Abstract][Full Text] [Related]
25. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
Ahmed IA; Kelly SB; Anderson JJ; Angus B; Challen C; Lunec J
Colorectal Dis; 2008 May; 10(4):344-51. PubMed ID: 17949449
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
27. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer.
Paradiso A; Simone G; Lena MD; Leone B; Vallejo C; Lacava J; Dellapasqua S; Daidone MG; Costa A
Br J Cancer; 2001 Mar; 84(5):651-8. PubMed ID: 11237386
[TBL] [Abstract][Full Text] [Related]
28. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
Ishida H; Ohsawa T; Nakada H; Yokoyama M; Inokuma S; Shirakawa K; Yamada H; Hashimoto D
Gan To Kagaku Ryoho; 2004 Jun; 31(6):883-7. PubMed ID: 15222105
[TBL] [Abstract][Full Text] [Related]
29. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival.
Bathe OF; Franceschi D; Livingstone AS; Moffat FL; Tian E; Ardalan B
Cancer J Sci Am; 1999; 5(1):34-40. PubMed ID: 10188059
[TBL] [Abstract][Full Text] [Related]
30. Clinical value of mitochondrial mutations in colorectal cancer.
Lièvre A; Chapusot C; Bouvier AM; Zinzindohoué F; Piard F; Roignot P; Arnould L; Beaune P; Faivre J; Laurent-Puig P
J Clin Oncol; 2005 May; 23(15):3517-25. PubMed ID: 15908662
[TBL] [Abstract][Full Text] [Related]
31. MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients.
Lizard-Nacol S; Genne P; Coudert B; Riedinger JM; Arnal M; Sancy C; Brunet-Lecomte P; Fargeot P
Anticancer Res; 1999; 19(4C):3575-81. PubMed ID: 10629655
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
[TBL] [Abstract][Full Text] [Related]
33. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
35. Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292).
Wadler S; Bajaj R; Neuberg D; Agarwal V; Haynes H; Benson AB
Cancer J Sci Am; 1997; 3(5):284-8. PubMed ID: 9327152
[TBL] [Abstract][Full Text] [Related]
36. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors.
Mini E; Biondi C; Morganti M; Napoli C; Mazzoni P; Cianchi F; Tonelli F; Cortesini C; Capaccioli S; Ficari F; Quattrone A; Rossi S; Mazzei T
Oncol Res; 1999; 11(9):437-45. PubMed ID: 10821538
[TBL] [Abstract][Full Text] [Related]
37. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
39. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
Thirion P; Michiels S; Pignon JP; Buyse M; Braud AC; Carlson RW; O'Connell M; Sargent P; Piedbois P;
J Clin Oncol; 2004 Sep; 22(18):3766-75. PubMed ID: 15365073
[TBL] [Abstract][Full Text] [Related]
40. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
Lin PC; Chen WS; Chao TC; Yang SH; Tiu CM; Liu JH
Cancer Chemother Pharmacol; 2007 Aug; 60(3):351-6. PubMed ID: 17111120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
